|Infectious Diseases Summit|
Antiviral Drugs Research & Development
Vaccines Research & Development
Anti-Infectives Partnering & Deal-Making
Recent headlines have been captivated by emerging infectious diseases from the recent Ebola outbreak in west Africa, to Zika in South America, to pandemic influenza around the globe. These emerging infections have been at the forefront of cutting-edge research, rapid product development and clinical evaluation and we are excited to invite you to join with colleagues from industry and academia to discuss them at GTCbio’s 15th Annual Vaccines Research & Development Conference. This meeting will take place July 13-14, 2017 in Baltimore, MD as part of the larger Infectious Diseases Summit.
Current support by NIH, DoD and BARDA, Eli Lilly, GlaxoSmithKline and more demonstrate recognition by federal agencies and large pharmaceutical companies the necessity for innovative vaccines for emerging pathogens. Therefore, the focus of this conference will be to evaluate the lessons learned from both the academic and industry responses during past epidemics for translation to next-generation research with new pathogens for use in future outbreaks. Sessions will focus on defining emerging global health threats (Zika, multi-drug resistant TB, influenza), discussing next generation technologies to address these foes (novel adjuvants, DC vaccines, nucleic acid vaccines, recombinant viral vectors) and addressing challenges to those goals.
Additionally, we will have a session focused on how best to create these assets for those most vulnerable – populations on both ends of the age spectrum – a topic that has recently arose as an important consideration. Over the course of this meeting attendees will have ample opportunity to engage and network with speakers and panelists.
- Plenary Session: Responding to Emerging Infectious Diseases on the Global Stage
- Vaccines for Infectious Diseases-Old & New Challenges
- Next-Generation Vaccine Technologies
- Enhancing Immunity at Both Ends of the Age Spectrum
- Panel: Clinical Trial Design during Epidemics
- General Session: Public/Private Partnerships in Support of Global Health
We hope to see you there!
The 2017 Advisory Committee
|2017 Program Director|
|Alyson Smith, University of Montana, Inimmune Corp.|
|2017 Advisory Board Members|
|Ken Rosenthal, Roseman University of Health Sciences|
|Lynda Tussey, VaxInnate Corporation|
|Daniel Wolfe, Biomedical Advanced Research and Development Authority|
|Steven Bradfute, University of New Mexico|
|Shan Lu, University of Massachusetts Medical School|
|Suresh Mahalingam, Griffith University|
|Jeffrey Ulmer, GSK Vaccines|
|Steve Pascolo, University Hospital Zurich|
|Tong-Ming Fu, Merck|
|Annie De Groot, EpiVax|
|Dan Zimmerman, CEL-SCI Corporation|
|Richard Kornbluth, Multimeric Biotherapeutics, Inc.|
|Lenny Moise, EpiVax|
|Jay Evans, Inimmune Corp.|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.